Navigation Links
Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:5/13/2008

s is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 The report, "Synthetic ... Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene ... Biomaterials, Bioremediation) - Global Forecast to 2018", ... threats, opportunities, and challenges. , Browse 99 ... through 185 pages and in-depth TOC of ...
(Date:11/21/2014)... November 21, 2014 Why did Stephen ... Albert Einstein so instantly recognizable? Why have they become ... astronomer and author Hilton Ratcliffe seeks out the answers ... at all to do with science. In " Stephen ... , November 21, 2014), Ratcliffe puts it plainly: ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and nine month periods ended September 30, 2014.  Biorem,s complete 2014 ... ( www.sedar.com ). Financial Summary:Three-months ended September ... except per share data) , 2014 , ... 2,282 , 5,281 , 6,715 ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3
... Brings Together,Policy and Innovation Experts, WASHINGTON, ... health,care economists and physician-innovators today highlighted the ... care and helping to,reduce health care costs. ... Innovation, Patients, Society," was part of AdvaMed ...
... Stanford, Berkeley, UPenn Partner with ... SANTA CRUZ, Calif., Oct. 2 According to the ... and,post-doctorates are in the United States today. With only ... universities, there,is an emerging need to find more quality ...
... Hall of Fame Coach Jim Calhoun Credits Early ... Day two of AdvaMed 2007:,The MedTech Conference will ... in medical technology as well as speakers on the,diversity ... technology,sector. The conference runs Oct. 1 through Oct. 3., ...
Cached Biology Technology:Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference 2Top Health Care Economists and Physician-Innovators Discuss Value of Medical Technology at AdvaMed 2007 Conference 3Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 2U.S. Commerce Secretary Gutierrez to Address AdvaMed 2007 3
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2
... known as the winter vomiting bug, is one of the ... highly contagious, causing vomiting and diarrhea, and the number of ... have to let the virus run its course for a ... associated with outbreaks of hNoV but it remains difficult to ...
... home to countless microorganisms that we can,t see, but these ... known as the skin microbiome - contribute to our health ... from pathogens, and mediating skin disorders. In a new study, ... in a contact sport, using roller derby as their model ...
... French . Researchers at the University of Montreal,s ... new mechanism that allows some cells in our body to move ... soldiers depicted in the Asterix series. Collective cell migration is an ... is also used by cancerous cells to disseminate efficiently in the ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
... polyclonal antibody to human XAB2 (amino terminus) ... identified through its interaction with XPA. Immunoprecipitation ... of XAB2 interacts with the transcription-coupled repair-specific ... with RNA polymerase II. Microinjection experiments with ...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: